Peroxisome Proliferator-Activated Receptors in Diabetic Nephropathy

Table 1

Animal studies.

Authors	TZD	Animal model	Duration	Effect on UAE	Effect on BP	Other effects
Model of type 1 diabetes
Fujii et al. [54]	Tro	STZ-induced diabetic rats	12 weeks	↓	NS	ND
Isshiki et al. [56]	Tro	STZ-induced diabetic rats	12 weeks	↓	ND	Hyperfiltration ↓
Nicholas et al. [58]	Tro	STZ-induced diabetic rats	12 weeks	↓	NS	ND
Yamashita et al. [60]	Tro, pio	STZ-induced diabetic SHR rats	12 weeks	↓	NS	Loss of glomerular basement membranes ↓
Model of type 2 diabetes
Yoshioka et al. [51]	Tro	Obese Zucker rats	4 and 8 weeks	↓	↓	ND
Fujiwara et al. [55]	Tro	Wistar fatty rats	24 weeks	↓	↓	ND
Yoshimoto et al. [50]	Pio	Diabetic Wistar fatty rats	13 weeks	↓	↓	Glomerulosclerosis ↓ intrarenal arteriolosclerosis ↓
Tanimoto et al. [59]	Pio	Diabetic KK/Ta mice	4 and 8 weeks	↓	NS	Glomerular enlargement ↓
Buckingham et al. [53]	Rosi	Obese Zucker rats	4 and 9 months	↓	↓	Glomerulosclerosis ↓ tubulointerstitial fibrosis ↓
Baylis et al. [52]	Rosi	Obese Zucker rats	6 months	↓	NS	Glomerulosclerosis ↓ tubulointerstitial fibrosis ↓
Khan et al. [57]	Rosi	Obese Zucker rats	12 weeks	↓	↓	ND

TZD, thiazolidinedione; Tro, troglitazone; Pio, pioglitazone; Rosi, rosiglitazone; STZ, streptozotocin; SHR, spontaneously hypertensive rats; UAE, urinary albumin excretion; BP, blood pressure; NS, no significant effects; ND: not determined; ↓, significant reductions.